Ligand id: 6880

Name: daclizumab

1. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M et al.. (2015)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N. Engl. J. Med., 373 (15): 1418-28. [PMID:26444729]
2. Queen CL, Schneider WP, Selick HE. (1997)
Genetic engineering; complementarity zones.
Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.
3. Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J. (2016)
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Clin Pharmacol, 8: 9-13. [PMID:26929672]